| References: |
In cell-based assay, CH5183284 prevents autophosphorylation of FGFR1, FGFR2, and FGFR3 at 100 to 300 nM in the DMS114 (FGFR1 amplification), SNU-16 (FGFR2 amplification), and KMS11 [t(4;14) translocation and FGFR3 Y373C mutation] cell lines. CH5183284 thus produces selective antiproliferative activity against cancer cell lines harboring genetic alterations in FGFR. CH5183284 also inhibit FGFR2 harboring one type of the gatekeeper mutation (V564F) that causes resistance to other FGFR inhibitors. CH5183284 (100 mg/kg/day, p.o.) shows selective and significant antitumor activity against xenografts with FGFR genetic alterations such as KG1 (leukemia, FGFR1OP-FGFR1 fusion), SNU-16 (gastric cancer, FGFR2 amplification), MFE-280 (endometrial cancer, FGFR2 S252W mutation), UM-UC-14 (bladder cancer, FGFR3 S249C mutation), and RT112/84 (bladder cancer, FGFR3-TACC3 fusion). For the detailed information of CH5183284 (Debio-1347), the solubility of CH5183284 (Debio-1347) in water, the solubility of CH5183284 (Debio-1347) in DMSO, the solubility of CH5183284 (Debio-1347) in PBS buffer, the animal experiment (test) of CH5183284 (Debio-1347), the cell expriment (test) of CH5183284 (Debio-1347), the in vivo, in vitro and clinical trial test of CH5183284 (Debio-1347), the EC50, IC50,and affinity,of CH5183284 (Debio-1347), For the detailed information of CH5183284 (Debio-1347), the solubility of CH5183284 (Debio-1347) in water, the solubility of CH5183284 (Debio-1347) in DMSO, the solubility of CH5183284 (Debio-1347) in PBS buffer, the animal experiment (test) of CH5183284 (Debio-1347), the cell expriment (test) of CH5183284 (Debio-1347), the in vivo, in vitro and clinical trial test of CH5183284 (Debio-1347), the EC50, IC50,and affinity,of CH5183284 (Debio-1347), Please contact DC Chemicals. |
